This review is intended as an educational resource for emergency department (ED) healthcare professionals who encounter patients who are (or have been) on immune checkpoint inhibitor (ICI) therapy for cancer and may be experiencing adverse reactions potentially attributable to the ICI. It reviews the identification and management of immune-related adverse reactions (irARs) in patients presenting to the ED, using current clinical consensus. The review also discusses two case studies of patients presenting to the ED with irARs.
Please login below to download this issue (PDF)